Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

(2022) Lawrence Steinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

(2021) Ludwig Kappos et al.   JAMA Neurology

Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis

(2021) Zhuoyi Liu et al.   AUTOIMMUNITY REVIEWS

Treatment of Multiple Sclerosis: A Review

(2020) Stephen L. Hauser et al.   AMERICAN JOURNAL OF MEDICINE

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

(2020) Imtiaz A Samjoo et al.   Journal of Comparative Effectiveness Research

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

(2019) Huihui Li et al.   JOURNAL OF NEUROLOGY

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis

(2019) Rachael McCool et al.   Multiple Sclerosis and Related Disorders

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis

(2018) Rosa C. Lucchetta et al.   CNS DRUGS

Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses

(2018) Shijie Ren et al.   MEDICAL DECISION MAKING

A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data

(2018) Claire Watkins et al.   Research Synthesis Methods

Multiple sclerosis

(2018) Massimo Filippi et al.   Nature Reviews Disease Primers

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

(2017) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

(2016) Emer Fogarty et al.   Multiple Sclerosis and Related Disorders

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis

(2014) Rebecca M. Turner et al.   STATISTICS IN MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

(2013) Jeroen P Jansen et al.   BMC Medicine

Evidence Synthesis for Decision Making 3

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

Evidence Synthesis for Decision Making 4

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

(2012) Georgia Salanti   Research Synthesis Methods

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

(2011) David C. Hoaglin et al.   VALUE IN HEALTH

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET